LONDON -- Company news is starting to pick up again after a lull over Easter. We don't have a great volume of updates expected, but we should be hearing from a handful of top�FTSE 100�firms. Here are three popular companies due to enlighten us next week:
Tesco
Next Wednesday, April 17, brings us one of the most hotly awaited company announcements of 2013 so far -- full-year results from�Tesco� (LSE: TSCO ) . (NASDAQOTH: TSCDY ) After the U.K.'s biggest supermarket had a weak Christmas in 2011, and saw its share price slump as a result,�Warren Buffett�famously bought in big. And he's done well so far -- from a 52-week low of 295 pence back in June last year, Tesco shares are now back up 30%, to 385 pence.
January's update told us of significantly better Christmas and New Year trading this time, with group sales for the six weeks to Jan. 5 up 3.5% (3.9% excluding petrol), and we heard that the U.K. in-store turnaround plan was bearing fruit. Since then, Tesco has announced the purchase of the Giraffe restaurant chain, buying up 49 restaurants for a little under 49 million pounds.
Top Rising Companies To Invest In 2015: Superior Energy Services Inc.(SPN)
Superior Energy Services, Inc. provides specialized oilfield services and equipments to serve the production and drilling-related needs of oil and gas companies. It operates through three segments: Subsea and Well Enhancement; Drilling Products and Services; and Marine. The Subsea and Well Enhancement segment provides integrated subsea and engineering services, coiled tubing, electric line, pumping and stimulation, gas lift, well control, hydraulic workover and snubbing, recompletion, stimulation and sand control equipment and services, well evaluation, offshore oil and gas tank, vessel cleaning, decommissioning, plug and abandonment, and mechanical wireline services. This segment also manufactures and sells drilling rig instrumentation equipments; and involves in the production and sale of oil and gas from its properties in the Gulf of Mexico. The Drilling Products and Services segment manufactures, sells, and rents equipments for use with offshore and onshore oil and gas well drilling, completion, production, and workover activities. This segment?s products and services include pressure control equipment, drill pipe and landing strings, connecting iron, handling tools, stabilizers, drill collars, and on-site accommodations. The Marine segment owns and operates a fleet of liftboats in the Gulf of Mexico. The company operates 25 rental liftboats with leg lengths ranging from 145 feet to 265 feet. Superior Energy Services, Inc. sells its products and services in Latin America, North America, North Sea and Europe, the Middle East, West Africa, and the Asia Pacific region. The company was founded in 1991 and is based in New Orleans, Louisiana.
Advisors' Opinion:- [By Sara Murphy]
Basic Energy Services (NYSE: BAS ) derived more than a quarter of 2012 revenues from its fluid services unit. Its operations rely heavily on the legacy model of hauling water. Superior Energy Services (NYSE: SPN ) counts on its traditional fluid services offerings for about 20% of revenues.
- [By Ben Levisohn]
As a result, the knives have come out. Cowen’s analysts downgraded six stocks–Baker Hughes (BHI), Cameron International (CAM), Nabors Industries (NBR), CGG (CGG), Superior Energy Services (SPN) and Helmerich & Payne (HP)–and cut their estimates on even more. Its analysts explain why:
5 Best Supermarket Stocks To Buy Right Now: Astrotech Corporation(ASTC)
Astrotech Corporation operates as a commercial aerospace company in the United States. The company provides spacecraft payload processing and related services; designs and manufactures space hardware; and commercializes space technologies for use on the earth. It also offers satellite launch processing support to government and commercial customers for their communication, earth observation, and deep space satellites. The company?s processing activities consist of satellite ground transportation; pre-launch hardware integration and testing; satellite encapsulation, fueling, launch pad delivery; and communication linked launch control, as well as engineering services. In addition, it develops Miniature Chemical Detector, a chemical analyzer for use on international space station, as well as detects residues and vapors from a range of chemicals, including explosives, chemical warfare agents, toxic chemicals, and volatile organic compounds. The company serves the United Stat es Government and commercial satellite and spacecraft customers. Astrotech Corporation was founded in 1984 is headquartered in Austin, Texas.
Advisors' Opinion:- [By Roberto Pedone]
Astrotech (ASTC) operates as a commercial aerospace company in the U.S. This stock closed up 7.2% to $3.26 a share in Thursday's trading session.
Thursday's Range: $3.02-$3.31
52-Week Range: $0.61-$4.05
Thursday's Volume: 295,000
Three-Month Average Volume: 570,805From a technical perspective, ASTC spiked sharply higher here right above some near-term support at $2.96 with lighter-than-average volume. This stock has been uptrending strong for the last four months, with shares moving higher from its low of 63 cents per share to its recent high of $4.05. During that uptrend, shares of ASTC have been making mostly higher lows and higher highs, which is bullish technical price action. This spike on Thursday is now starting to push shares of ASTC within range of triggering a major breakout trade. That trade will hit if ASTC manages to take out some near-term overhead resistance levels at $3.50 to $3.75 and then once it takes out its 52-week high at $4.05 with high volume.
Traders should now look for long-biased trades in ASTC as long as it's trending above its 50-day at $2.66 or above more near-term support at $2.62 and then once it sustain a move or close above those breakout levels with volume that hits near or above 570,805 shares. If that breakout hits soon, then ASTC will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets of that breakout are $5 to $5.50.
- [By Quick Pen]
American aerospace and defense giant Lockheed Martin (LMT) recently announced its plans of acquiring the satellite wing of Astrotech Corp. (ASTC), Astrotech Space Operations. Lockheed expects to close the deal by the third quarter of the current year. After the deal closes, Astrotech Space Operations would become the wholly owned subsidiary of Lockheed Martin and would operate under the company�� Space Systems business segment.
5 Best Supermarket Stocks To Buy Right Now: China Eastern Airlines Corp Ltd (CEA)
China Eastern Airlines Corporation Limited (China Eastern), incorporated on April 14, 1985, is an air carriers operating in the People�� Republic of China. As of December 31, 2010, the Company served a route network that covers 182 domestic and foreign cities in 30 countries. It operates from Shanghai�� Hongqiao International Airport and Pudong International Airport. During the year ended December 31, 2010, its flights accounted for 52.2% and 37.9% of all the flight traffic at Hongqiao International Airport and Pudong International Airport, respectively. During 2010, it accounted for approximately 31.1% of the total passenger traffic volume and 19% of the total freight volume on routes to and from Shanghai. As of December 31, 2010, it had a fleet of 355 aircraft, including 337 passenger jets each with a seating capacity of over 100 seats and 18 freighters.
Passenger Operations
During 2010, the Company operated approximately 9,600 scheduled flights per week, excluding charter flights, serving a route network that covers 182 domestic and foreign cities in 30 countries. During 2010, its domestic routes generated approximately 71.5% of its passenger revenues. Its heavily traveled domestic routes link Shanghai to the commercial and business centers of the People�� Republic of China, such as Beijing, Guangzhou and Shenzhen. During 2010, it also operated approximately 361 flights per week to and from Hong Kong, originating from Shanghai and 16 major cities in eastern, northern and western the People�� Republic of China. During 2010, it operated approximately 103 flights per week between mainland China and Taiwan. During 2010, its regional routes accounted for approximately 5.4% of its passenger revenues. During 2010, it operated approximately 1,079 international flights per week, serving 60 cities in 29 countries, linking Shanghai to cities in Asian and Southeast Asian countries, such as Japan, Korea, India, Singapore, Thailand and Bangladesh and locations in Europe, the Un! ited States and Australia.
During 2010, the Company re-started its Shanghai to London and Shanghai to Moscow routes. During 2010, revenues derived from its operations on international routes accounted for approximately 23.2% of its passenger revenues. During 2010, revenues derived from its operations to and from Japan accounted for approximately 7.7% of its passenger revenues and approximately 33.4% of its international passenger revenues. Its international and regional flights and a portion of its domestic flights either originate or terminate in Shanghai, the central hub of its route network. Its operations in Shanghai are conducted at Hongqiao International Airport and Pudong International Airport. On March 16, 2010, it moved its operations at Hongqiao International Airport to the terminal two of Hongqiao International Airport. It operates its flights through three hubs located in eastern, northwestern and southwestern China, namely Shanghai, Xi��n and Kunming, respectively.
Cargo and Mail Operations
The Company�� cargo and mail business utilizes the same route network used by its passenger airline business. It carries cargo and mail on its freight aircraft, as well as in available cargo space on its passenger aircraft. Its cargo and mail routes are international routes. As of December 31, 2010, it had seven MD-11F, four B777F and two B757-200F freight aircraft under operating leases for cargo and mail operations. It also has three Airbus A300-600R aircraft, as well as two Boeing 747-400ER freighters for its cargo operations.
The Company competes with Air China Limited, China Southern Airlines Company Limited, Hong Kong Dragon Airlines Limited, Cathay Pacific Airways, Thai Airways International, Singapore Airlines, Delta Air Lines, United Airlines, American Airlines, Air Canada, Delta, Alitalia, Air France-KLM Group, Asiana Airlines, Korean Air, Virgin Atlantic Airways, British Airways, Lufthansa German Airlines, Aeroflot and Qantas Airways.
Advisors' Opinion:- [By Belinda Cao]
The Bloomberg China-US Equity Index (CH55BN) of the most-traded Chinese companies in the U.S. slumped 3.4 percent last week to a seven-month low of 89.04. The gauge traded at 13.5 times estimated earnings, 3.6 percent below the S&P�� valuation, data compiled by Bloomberg show. China Southern Airlines Co. (ZNH) and China Eastern Airlines Corp. (CEA) lost more than 6 percent April 5, while Home Inns & Hotels Management Inc. (HMIN) tumbled 16 percent in the week.
5 Best Supermarket Stocks To Buy Right Now: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By George Budwell]
Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV ) , Enanta Pharmaceuticals (NASDAQ: ENTA ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�
- [By James Fink]
And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).
- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi.
No comments:
Post a Comment